BMO Capital Markets gave Halozyme (HALO 0.34%) an upgrade today, pushing the company's price target up from $4 to an incredible $12, which has shares up 15%. In the following video, Motley Fool health care analyst David Williamson takes us through BMO's thought process for an upgrade and Halozyme's upcoming catalysts.
Is Halozyme Back?
By Dave Williamson and Max Macaluso – Jan 14, 2013 at 3:50PM
NASDAQ: HALO
Halozyme Therapeutics
Market Cap
$8.0B
Today's Change
(-0.34%) $0.23
Current Price
$68.01
Price as of November 10, 2025 at 4:00 PM ET
Can this pharma company make a comeback?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid